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Abstract 
Introduction 
The aim of this study was to assess long-term golimumab therapy in rheumatoid arthritis 
(RA) patients who discontinued previous tumor necrosis factor-α (TNF)-inhibitor(s). 
Methods 
Patients enrolled into this multicenter, randomized, double-blind, placebo-controlled study of 
active RA (≥4 tender, ≥4 swollen joints) received placebo (Group 1) or golimumab 50 mg 
(Group 2) or 100 mg (Group 3) injections every 4 weeks. Patients in Groups 1 and 2 with 
inadequate response at week 16 escaped to golimumab 50 and 100 mg, respectively. At week 
24, Group 1 patients crossed-over to golimumab 50 mg, Group 2 continued golimumab 
50/100 mg per escape status, and Group 3 maintained dosing. During the long-term-extension 
(LTE), golimumab 50 mg could be increased to 100 mg, and 100 mg could be decreased to 
50 mg. Data through 5 years are reported for all patients (safety) and patients using 
methotrexate (efficacy, intention-to-treat (ITT) analysis with last-observation-carried-forward 
for missing data and non-responder imputation for unsatisfactory efficacy discontinuations). 
Results 
In total, 459 of 461 randomized patients received the study agent, 304 of whom were 
methotrexate-treated and included in efficacy analyses. Through week 256, the proportions of 
methotrexate-treated patients achieving American-College-of-Rheumatology (ACR) 
responses were 37.6% to 47.0% for ACR20, 21.4% to 35.0% for ACR50, and 7.8% to 17.0% 
for ACR70 response across randomized groups. Golimumab safety through week 268 was 
generally consistent with that at week 24 and week 160 and other anti-TNF agents. 
Conclusions 
In some patients with active RA discontinuing previous TNF-antagonist therapy, golimumab 
safety and efficacy, assessed conservatively with ITT analyses, was confirmed through 5 
years. 
Trial registration 
Clinicaltrials.gov NCT00299546. Registered 03 March 2006. 
Introduction 
GO-AFTER (GOlimumab After Former anti-tumor necrosis factor α Therapy Evaluated in 
Rheumatoid arthritis; Trial registration: Clinicaltrials.gov NCT00299546; registered March 
03, 2006) was the first and hitherto only prospective, randomized, phase 3, double-blind, 
placebo-controlled trial to assess a tumor necrosis factor-α (TNF)-inhibitor exclusively in 
patients with active rheumatoid arthritis (RA) who previously received TNF-inhibitor(s). 
Patients had also received several disease-modifying antirheumatic drugs (DMARDs) prior to 
TNF-inhibitor(s), thereby representing a difficult-to-treat population. As reported previously, 
treatment with golimumab 50 mg or 100 mg every 4 weeks yielded significantly higher 
ACR20 (≥20% improvement in the American College of Rheumatology criteria) response 
rates than treatment with placebo at week 14.[1,2] At week 160 of the GO-AFTER trial, 
golimumab 50-mg and 100-mg injections every 4 weeks resulted in persistent improvement 
in signs and symptoms of RA and physical function among patients who continued therapy 
throughout this observation period of 3 years.[2] 
Long-term extension (LTE) phases of clinical trials typically are associated with special 
concerns in data reporting because of the bias resulting from assessment only of patients who 
were responding to treatment and who continued study participation [3]. However, both 
patients and providers can benefit from assessing the outcome of patients who respond to 
treatment, as well as the outcome in all patients who started a specific therapy. Needless to 
say, it is particularly challenging for patients with disease refractory to several prior 
therapies, including biological agents as was the case for the GO-AFTER study population 
[1,2], to achieve and maintain clinical responses. 
The GO-AFTER study was designed to include a LTE phase of golimumab therapy. These 5-
year data, which comprise the entire planned trial, are reported herein and include 
information about long-term safety in this patient population. 
Methods 
The GO-AFTER study was conducted according to the Declaration of Helsinki. All patients 
provided written informed consent, and the protocol was approved by each institution’s 
ethical review board (see Acknowledgments for details). 
Details of the GO-AFTER (NCT00299546) patients with RA [4] and methods have been 
reported previously; procedures and analyses specific to the LTE, including assessments of 
clinical response, quality of life, safety and immunogenicity, [5-14] are summarized in 
Additional file 1. 
Results 
Patient disposition and baseline patients and disease characteristics 
Patient disposition through week 24 [1] and week 160 [2] of GO-AFTER has been reported 
previously. Through week 252, 276 (60.1%) patients discontinued study agent (Additional 
file 1: Figure S1), most commonly because of unsatisfactory therapeutic effect (n = 107), 
adverse events (n = 86), and “other” reasons (n = 69). The proportions of patients 
discontinuing study agent due to adverse events or unsatisfactory therapeutic effect increased 
with greater number of TNF-antagonists taken (data not shown). Baseline methotrexate 
(MTX) use was reported by 311 treated patients. Among these, 58.2% (181/311) 
discontinued study agent. In patients receiving golimumab monotherapy, 64.2% (95/148) 
discontinued study agent. Baseline patient/disease characteristics have been reported [1,2] 
and are summarized in Additional file 1: Table S1. During the LTE, 139 patients escalated 
golimumab dose (from 50 mg to100 mg) and 29 patients reduced dose (from 100 mg to 50 
mg) at the investigator’s discretion (Additional file 1: Figure S1). 
Clinical outcomes 
As reported previously, at week 24 the proportions of all patients achieving ACR20 response, 
ACR50 response, 28-joint Disease Activity Score (DAS28) response and DAS28 score < 2.6 
among patients who received golimumab 50 mg and 100 mg were significantly higher than 
for placebo-treated patients (all p < 0.05) [1]. 
Clinical outcomes through 5 years are primarily summarized using an intent-to-treat (ITT) 
analysis. Given that all patients received golimumab from week 16 or 24, no treatment group 
comparisons were undertaken. Based on ITT efficacy data, the proportions of MTX-treated 
patients who achieved ACR20, ACR50, DAS28 employing C-reactive protein (DAS28-CRP) 
response, and DAS28-CRP scores < 2.6 and < 3.2 were consistent through week 256. At this 
time, 37.9% (39/103) of patients randomized to receive placebo and then golimumab from 
week 16 (early escape) or week 24 onward and 42.3% (85/201) of golimumab-randomized 
patients achieved ACR20 response; 21.4% (22/103) and 29.9% (60/201), respectively, 
achieved ACR50 response; 56.3% (58/103) and 59.7% (120/201) achieved DAS28-CRP 
response; 18.4% (19/103) and 15.4% (31/201) achieved DAS28-CRP < 2.6; and 26.2% 
(27/103) and 29.9% (60/201) achieved DAS28-CRP < 3.2 (Figure 1A-E). Clinical remission, 
defined as Simplified Disease Activity Index (SDAI) ≤ 3.3, was achieved by 6.8% (7/103) 
and 8.5% (17/201) of placebo- and golimumab-randomized patients, respectively, at week 
256 (Figure 1F). At week 256, 37.9% (39/103) and 43.8% (88/201) of patients, respectively, 
achieved ≥ 0.25-unit improvement in the Health Assessment Questionnaire Disability Index 
(HAQ-DI) score (Figure 1G). Similar trends were evident when responses were assessed as 
observed data, albeit at higher rates due to the ‘completer’ nature of those analyses 
(Additional file 1: Figure S2). 
Figure 1 Clinical efficacy over time through week 256, including ACR20 (A), ACR50 
(B), DAS28-CRP response (C), DAS28-CRP score < 2.6 (D), DAS28-CRP score < 3.2 
(E), SDAI score ≤ 3.3 (F), and HAQ-DI improvement ≥ 0.25 (G). Data summarized for 
randomized patients receiving methotrexate at baseline, excluding one site, using intent-to-
treat methodology, with replacement of missing data by last-observation-carried forward 
methodology and imputation with baseline median values, and non-responder imputation for 
discontinuations due to unsatisfactory therapeutic effect. ACR20/50 = at least 20%/50% 
improvement in the American College of Rheumatology response criteria, CRP = C-reactive 
protein, DAS28 = 28-joint Disease Activity Score, HAQ-DI = Health Assessment 
Questionnaire Disability Index, SDAI = Simplified Disease Activity Index. 
Immunogenicity 
The overall cumulative incidence of antibodies-to-golimumab through week 268 was low 
(8.0%) and increased only slightly over time. Most of these patients tested positive for 
neutralizing antibodies (Table 1). 
Table 1 Cumulative summary of golimumab safety and immunogenicity through week 
268 of the GO-AFTER trial 
 Golimumab
 50 mg only 50 and 100 mg 100 mg only All patients
Number of treated patients 98 195 138 431 
Mean duration of follow-up (weeks) 129.82 187.45 162.06 166.22 
Mean number of injections 29.4 42.9 37.0 37.9 
Patients with 1 or more adverse events 90 (91.8%) 186 (95.4%) 132 (95.7%) 408 (94.7%) 
Common adverse events1     
     Upper respiratory tract infection 25 (25.5%) 49 (25.1%) 43 (31.2%) 117 (27.1%) 
     Rheumatoid arthritis 17 (17.3%) 57 (29.2%) 25 (18.1%) 99 (23.0%) 
     Nasopharyngitis 10 (10.2%) 37 (19.0%) 26 (18.8%) 73 (16.9%)
     Sinusitis 19 (19.4%) 35 (17.9%) 23 (16.7%) 77 (17.9%) 
     Back pain 8 (8.2%) 36 (18.5%) 18 (13.0%) 62 (14.4%) 
     Hypertension 10 (10.2%) 34 (17.4%) 17 (12.3%) 61 (14.2%) 
     Arthrlagia 13 (13.3%) 26 (13.3%) 21 (15.2%) 60 (13.9%) 
     Bronchitis 12 (12.2%) 24 (12.3%) 22 (15.9%) 58 (13.5%) 
     Diarrhoea 5 (5.1%) 28 (14.4%) 22 (15.9%) 55 (12.8%)
     Urinary tract infection 13 (13.3%) 25 (12.8%) 13 (9.4%) 51 (11.8%) 
     Nausea 10 (10.2%) 21 (10.8%) 18 (13.0%) 49 (11.4%) 
     Headache 14 (14.3%) 19 (9.7%) 14 (10.1%) 47 (10.9%) 
     Cough 10 (10.2%) 24 (12.3%) 13 (9.4%) 47 (10.9%) 
Death     
     Observed number of patients 2 (2.0%) 6 (3.1%) 1 (0.7%) 9 (2.1%) 
     Incidence (95% CI)/100 pt-yrs2 0.82 (0.10, 2.95) 0.85 (0.31, 1.86) 0.23 (0.01, 1.30) 0.65 (0.30, 1.24)
Discontinuation due to adverse event(s) 24 (24.5%) 33 (16.9%) 24 (17.4%) 81 (18.8%) 
Serious adverse events 34 (34.7%) 71 (36.4%) 46 (33.3%) 151 (35.0%) 
Common serious adverse events3     
     Pneumonia 3 (3.1%) 10 (5.1%) 5 (3.6%) 18 (4.2%)
     Urinary tract infection 0 5 (2.6%) 2 (1.4%) 7 (1.6%) 
     Rheumatoid arthritis 4 (4.1%) 8 (4.1%) 2 (1.4%) 14 (3.2%) 
     Osteoarthritis 2 (2.0%) 8 (4.1%) 1 (0.7%) 11 (2.6%) 
     Sepsis 0 5 (2.6%) 1 (0.7%) 6 (1.4%) 
     Arthralgia 1 (1.0%) 1 (0.5%) 2 (1.4%) 4 (0.9%) 
Infections 64 (65.3%) 149 (76.4%) 108 (78.3%) 321 (74.5%)
Serious infections     
     Observed number of patients 12 (12.2%) 29 (14.9%) 19 (13.8%) 60 (13.9%) 
     Observed number of serious infections 16 46 35 97 
     Incidence (95% CI)/100 pt-yrs4 6.54 (3.74, 10.62) 6.54 (4.79, 8.73) 8.14 (5.67, 11.32) 7.04 (5.71, 8.59)
Common serious infections5  
     Pneumonia 3 (3.1%) 10 (5.1%) 5 (3.6%) 18 (4.2%) 
     Urinary tract infection 0 5 (2.6%) 2 (1.4%) 7 (1.6%) 
     Sepsis 0 5 (2.6%) 1 (0.7%) 6 (1.4%) 
     Cellulitis 1 (1.0%) 2 (1.0%) 1 (0.7%) 4 (0.9%) 
     Diverticulitis 0 1 (0.5%) 2 (1.4%) 3 (0.7%) 
     Pneumonitis 1 (1.0%) 0 1 (0.7%) 2 (0.5%) 
     Colitis ulcerative 1 (1.0%) 0 0 1 (0.2%) 
     Diarrhoea 1 (1.0%) 0 0 1 (0.2%) 
     Vomiting 1 (1.0%) 0 0 1 (0.2%) 
Golimumab injection-site reactions     
     Patients with reactions 11 (11.2%) 24 (12.3%) 18 (13.0%) 53 (12.3%) 
     Injections with reactions 16 (0.6%) 49 (0.6%) 64 (1.3%) 129 (0.8%) 
Antibodies to golimumab     
     Week 52 5 (5.4%) 9 (5.4%) 6 (4.6%) 20 (5.2%) 
         % with neutralizing antibodies6 3/4 (75.0%) 5/5 (100.0%) 6/6 (100.0%) 14/15 (93.3%) 
     Week 100 6 (6.5%) 12 (7.2%) 7 (5.4%) 25 (6.4%) 
         % with neutralizing antibodies6 4/5 (80.0%) 10/10 (100.0%) 6/7 (85.7%) 20/22 (90.9%)
     Week 268 7 (7.6%) 16 (9.6%) 8 (6.2%) 31 (8.0%) 
         % with neutralizing antibodies6 5/6 (83.3%) 14/14 (100.0%) 6/8 (75.0%) 25/28 (89.3%) 
1 Occurring in ≥ 10% of patients in the combined golimumab group. 
2 The incidence of death for placebo through week 24 was 0.00 (95% CI 0.00, 6.20). 
3 Occurring in ≥ 1% of patients in any golimumab group. 
4 The incidence of serious infections for placebo through week 24 was 2.07 (95% CI 0.05, 11.52). 
5 Occurring in ≥ 1% of patients in any golimumab group. 
6 Among patients with samples evaluable for testing. 
CI = confidence interval (based on exact method), pt-yrs = patient-years of follow-up. 
Data presented are number (%) of patients unless noted otherwise. 
Adverse events 
Adverse events through week 24 and week 160 of the GO-AFTER trial have been reported 
previously [1,2]. Eleven patients died through week 268, including one placebo-treated 
patient who died of pancreatic cancer during the 24-week study period [1] and 10 
golimumab-treated patients who died after week 24 (Table 1). No predominant cause of death 
was identified throughout the 5-year trial (see Additional file 1). 
Serious adverse events were reported for approximately one-third of golimumab-treated 
patients, with the most common categorized as infections. Infections were also the most 
common adverse events leading to study agent discontinuation (Table 1). The overall pattern 
and types of infections observed through week 268 were similar to those reported through 
week 24 [1]. Through week 268, 13.9% of patients in the combined golimumab group had ≥1 
infection identified by the investigator as a serious adverse event (Table 1). One case of 
active tuberculosis (pulmonary) was reported for a patient who was receiving golimumab 100 
mg. Histoplasmosis infection occurred in two patients, each judged to be a serious infectious 
event (one disseminated, with both patients receiving golimumab 100 mg at event onset). 
Four patients had opportunistic infections through week 268, including three patients with 
esophageal candidiasis (1 patient who was receiving 50 mg, 2 patients who were receiving 
100 mg) and one with ophthalmic herpes zoster (100 mg). 
Twenty patients in the combined golimumab-treated group had malignancies reported 
through week 268, including lymphoma (4 patients who were receiving golimumab 100 mg) 
and nonmelanoma skin cancers. The 95% confidence intervals (CIs) surrounding the 
incidence/100 pt-yrs of all malignancy categories observed with golimumab were contained 
within the 95% CI for placebo through week 24 (i.e., 0.00 [0.00, 6.20]). The standardized 
incidence ratio (SIR) and surrounding 95% CI for lymphoma indicated a higher-than-
expected occurrence among patients who received golimumab 100 mg; however, the SIRs 
(95% CI) for all other malignancies (excluding nonmelanoma skin cancers, which are not 
captured in the Surveillance, Epidemiology, and End Results database) indicated no increased 
risk relative to the general US population (Table 2). See Additional file 1 for additional safety 
findings. 
Table 2 Number of patients with 1 or more malignancies through week 268 compared 
with the expected number of malignancies from the general United States population 
according to the SEER database 
 Golimumab
 50 mg only 50 and 100 mg 100 mg only All patients
Treated patients in the study 98 195 138 431 
All malignancies     
Observed number of patients 3 11 6 20 
     Incidence (95% CI)/100 pt-yrs1 1.23 (0.25, 3.59) 1.59 (0.79, 2.85) 1.42 (0.52, 3.10) 1.47 (0.90, 2.28) 
     SIR2 1.36 1.20 0.81 1.11 
     (95% CI)3 (0.28, 3.98) (0.48, 2.47) (0.17, 2.36) (0.59, 1.89) 
Type of malignancy     
Lymphoma   
     Observed number of patients 0 2 2 4 
     Incidence (95% CI)/100 pt-yrs1 0.00 (0.00, 1.22) 0.28 (0.03, 1.03) 0.47 (0.06, 1.68) 0.29 (0.08, 0.74) 
     SIR2 0.00 8.13 12.32 7.96 
     (95% CI)3 (0.00, 31.87) (0.99, 29.38) (1.49, 44.49) (2.17, 20.39) 
Other malignancies     
     Observed number of patients 3 5 1 9 
     Incidence (95% CI)/100 pt-yrs1 1.23 (0.25, 3.59) 0.71 (0.23, 1.66) 0.23 (0.01, 1.30) 0.65 (0.30, 1.24) 
     SIR2 1.42 0.89 0.28 0.80 
     (95% CI)3 (0.29, 4.15) (0.29, 2.07) (0.01, 1.56) (0.36, 1.51) 
Nonmelanoma skin cancer     
     Observed number of patients 0 5 3 8 
     Incidence (95% CI)/100 pt-yrs1 0.00 (0.00, 1.22) 0.72 (0.23, 1.69) 0.71 (0.15, 2.08) 0.59 (0.25, 1.16)
1 The incidences (95% CIs) for placebo through week 24 were 0.00 (0.00, 6.20) for lymphoma, 0.00 (0.00, 6.20) 
for nonmelanoma skin cancer, 0.00 (0.00, 6.20) for other malignancies, and 0.00 (0.00, 6.20) for all 
malignancies. 
2 SIR = Standardized Incidence Ratio (observed number of patients with malignancy based on the SEER 
database [14], adjusted for age, gender, and race divided by expected number of patients with malignancy). SIR 
(95% CI) for placebo through week 24 were 0.00 (0.00, 175.37) for lymphoma, 0.00 (0.00, 7.82) for other 
malignancies, and 0.00 (0.00, 7.51) for all malignancies. 
3 Confidence intervals based on an exact method. 
CI = confidence interval, pt-yrs = patient-years, SEER = Surveillance, Epidemiology, and End Results. 
Discussion 
The GO-AFTER trial evaluated patients with active RA despite prior treatment with 
conventional synthetic DMARDs and ≥ 1 TNF-inhibitor(s) (a particularly treatment-
refractory cohort with longstanding disease) for their response to yet another TNF-inhibitor, 
golimumab. The LTE data presented reveal that, despite refractory disease, 40% of 
randomized patients continued in the study through 5 years. Among completers, > 50% of 
patients randomized to golimumab + MTX maintained low disease activity according to 
DAS28 criteria and 15% attained remission according to stringent ACR-European League 
Against Rheumatism (EULAR) index-based criteria. Among all randomized patients, > 20% 
achieved low disease activity and approximately 8% achieved stringent remission criteria. 
For this treatment-resistant population, among whom approximately one-third had not 
received MTX and thus were less amenable to responding versus combination therapy [15], 
this is not necessarily expected. The data show that, indeed, the TNF-inhibitor golimumab 
can exert sustained significant efficacy in some patients who previously discontinued ≥ 1 
TNF-inhibitor. 
Similar LTE data have not been published for other biological agents, e.g., tocilizumab, 
rituximab, abatacept, and other TNF-inhibitors; therefore, indirect comparisons cannot be 
made. However, we have shown previously that 6-month response rates to golimumab plus 
MTX were similar to those of other targeted biologics in similar patient populations [1]. 
There are several limitations to the analyses after week 24. No patients received placebo after 
week 24, yielding no control group after this time point. Study drug was administered open-
label after the week 24 database lock. Patients could change golimumab treatment from 50 
mg to 100 mg (n = 139) and from 100 mg to 50 mg (n = 29) during the LTE according to 
investigator judgment. These uncontrolled dose changes limit conclusions regarding the 
effect of dose change. These changes in treatment regimens also hinder comparisons between 
the golimumab 50-mg and 100-mg dose groups. Exposure to golimumab 100 mg was 
substantially greater, both in number of patients and length of follow-up. Patients with more 
severe RA disease, who would likely be more difficult-to-treat and more prone to experience 
adverse events, may have been selectively escalated to the higher dose. These confounding 
factors preclude drawing definitive conclusions regarding the relative dose comparability. 
The safety data revealed no new findings as compared to earlier phases of the GO-AFTER 
trial [1,2], with serious infections occurring in 14% of the patients. When adjusted for length 
of follow-up, the incidence of serious infections among all golimumab-treated patients was 
7.04/100 pt-yr, which is consistent with those observed in a retrospective observational 
population-based inception cohort of patients diagnosed with RA between 1995 and 2007, 
i.e., 6.6/100 pt-yr for all patients and 8.2/100 pt-yr during treatment with biologic agents [16]. 
Of note, four 100-mg-treated patients developed lymphoma, a rate significantly higher than 
expected; all occurred within the first 3 years of observation [2]. No patient in the 50-mg 
group developed lymphoma. Lymphoma is associated with cumulative RA disease activity 
[17] and registry data have not shown an association between TNF-inhibitor treatment and 
increased lymphoma risk [18]. When adjusted for length of follow-up, the overall incidence 
of lymphoma reported herein (0.29/100 pt-yr) was higher than that previously reported based 
on a longitudinal (1998–2005) study of long-term outcomes of RA patients (0.11/100 pt-yr) 
[19]. However, due to the relatively small numbers of events and patients in our trial, the 
accompanying 95% CI was fairly wide (95% CI: 0.08, 0.74) and in fact overlapped that of the 
longitudinal trial that evaluated 19,591 patients for 89,710 pt-yrs of follow-up (95% CI: 0.09, 
0.13) [19]. Whether the increased rate we observed for the 100-mg dose is related to the drug 
dose itself or to the theoretically higher cumulative disease activity of patients receiving this 
dose due to dose escalation (see above and as discussed elsewhere [2]) remains unknown. 
Conclusion 
Golimumab can be an effective therapy over the long term for RA patients who have 
previously received and discontinued another TNF-inhibitor therapy for reasons including 
insufficient efficacy. Almost 40% of the patients originally randomized to golimumab 
continued therapy for 5 years and many achieved low disease activity/remission with this 
treatment, despite their refractory disease. 
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